Arger NK, et al. - Given that sarcoidosis patients have increased CXCL9 and CXCL10 [interferon-gamma-inducible chemotactic cytokines (chemokines)], yet crucial molecular differences are seen, so, researchers investigated whether there exists correlation of serum chemokines with different aspects of disease severity. Via ELISA, they measured CXCL9 and CXCL10 serum concentrations at initial study visits and longitudinally in sarcoidosis cases. They found a negative correlation of higher CXCL10 levels with forced vital capacity, total lung capacity, and diffusing capacity for carbon monoxide at participants’ initial visit and when assessed repeatedly over two years. A positive correlation of CXCL10 with longitudinal respiratory symptom severity was also identified. Overall, the correlation of serum CXCL9 levels with systemic organ involvement was evident in patients with sarcoidosis. Experts also identified a strong correlation of CXCL10 levels with respiratory outcomes in these individuals. These may prove valuable in clinical management. These distinct links may be attributable to differences in cellular regulation and tissue origin.